Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Summer;12(2):91-9.
doi: 10.1111/j.1527-3458.2006.00091.x.

Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data

Mauro A M Carai  1 , Giancarlo Colombo, Paola Maccioni, Gian Luigi Gessa
Affiliations
Review

Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data

Mauro A M Carai et al. CNS Drug Rev. 2006 Summer.

Abstract

The present paper focuses on the different lines of evidence indicating that cannabinoid CB(1) receptor antagonists, including the prototype rimonabant, reduce food intake and body weight in laboratory animals. Recent clinical surveys demonstrated that rimonabant significantly reduced body weight also in overweight/obese humans. Treatment with rimonabant was associated with a beneficial effect on different metabolic parameters and cardiovascular risk factors linked to overweight. The data reviewed in this paper suggest that cannabinoid CB(1) receptor antagonists may constitute a novel class of drugs potentially effective in the treatment of obesity-related disorders.

PubMed Disclaimer

References

    1. Anthenelli RM, Dale R. Rimonabant helps cigarette smokers stop smoking and prevents post cessation weight gain: Results from the STRATUS‐US trial In: Final Program and Abstracts of 6th Annual Conference of SRNT Europe; Tübingen, Germany , 2004: 35.
    1. Arnone M, Maruani J, Chaperon F, Thiébot ME, et al. Selective inhibition of sucrose and alcohol intake by SR 141716, an antagonist of central cannabinoid (CB 1) receptors. Psychopharmacology 1997; 132: 104–106. - PubMed
    1. Bensaid M, Gary‐Bobo M, Esclangon A, et al. T he cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/([a‐z])a rats and in cultured adipocyte cells. Mol Pharmacol 2003;63: 908–914. - PubMed
    1. Carai MAM, Colombo G, Gessa GL. Rimonabant: The first therapeutically relevant cannabinoid antagonist. Life Sci 2005;77: 2339–2350. - PubMed
    1. Chambers AP, Sharkey KA, Koopmans HS. Cannabinoid (CB)1 receptor antagonist, AM251, causes a sustained reduction of daily food intake in the rat. Physiol Behav 2004;82: 863–869. - PubMed

Publication types